Morgan Stanley
NUVB icon

Morgan Stanley’s Nuvation Bio NUVB Stock Holding History

Morgan Stanley’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.28M Sell
1,457,333
-413,884
-22% -$2.02M ﹤0.01% 3854
2026
Q1 		$8.03M Buy
1,871,217
+595,089
+47% +$3.32M ﹤0.01% 3757
2025
Q4 		$11.4M Sell
1,276,128
-43,367
-3% -$269K ﹤0.01% 3493
2025
Q3 		$4.88M Buy
1,319,495
+109,692
+9% +$299K ﹤0.01% 4170
2025
Q2 		$2.36M Sell
1,209,803
-760,167
-39% -$1.58M ﹤0.01% 4593
2025
Q1 		$3.47M Buy
1,969,970
+897,134
+84% +$2.04M ﹤0.01% 4221
2024
Q4 		$2.85M Sell
1,072,836
-110,035
-9% -$283K ﹤0.01% 4440
2024
Q3 		$2.71M Buy
1,182,871
+144,185
+14% +$440K ﹤0.01% 4440
2024
Q2 		$3.03M Sell
1,038,686
-142,915
-12% -$436K ﹤0.01% 4277
2024
Q1 		$4.3M Buy
1,181,601
+379,057
+47% +$728K ﹤0.01% 4024
2023
Q4 		$1.21M Buy
802,544
+358,046
+81% +$461K ﹤0.01% 4814
2023
Q3 		$596K Sell
444,498
-169,736
-28% -$283K ﹤0.01% 5088
2023
Q2 		$1.11M Buy
614,234
+165,593
+37% +$282K ﹤0.01% 4773
2023
Q1 		$745K Buy
448,641
+13,747
+3% +$27.9K ﹤0.01% 5032
2022
Q4 		$835K Buy
434,894
+234,120
+117% +$474K ﹤0.01% 4964
2022
Q3 		$449K Buy
200,774
+18,398
+10% +$52.5K ﹤0.01% 5319
2022
Q2 		$591K Buy
182,376
+62,824
+53% +$274K ﹤0.01% 5332
2022
Q1 		$629K Sell
119,552
-47,716
-29% -$268K ﹤0.01% 5273
2021
Q4 		$1.42M Buy
167,268
+90,409
+118% +$831K ﹤0.01% 4833
2021
Q3 		$764K Buy
76,859
+24,419
+47% +$221K ﹤0.01% 5230
2021
Q2 		$488K Buy
52,440
+1,890
+4% +$21.6K ﹤0.01% 5531
2021
Q1 		$528K Buy
50,550
+50,458
+54,846% +$564K ﹤0.01% 5123
2020
Q4 		$1K Buy
+92
New +$957 ﹤0.01% 6954

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley's NUVB Position: Q2 2026 in Review

Morgan Stanley reduced its Nuvation Bio (NUVB) stake by 22% in Q2 2026, selling an estimated $2.02M and leaving 1,457,333 shares worth $8.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3854.

Morgan Stanley first reported a position in NUVB in Q4 2020 and has held it in 23 quarters since. The position peaked at $11.4M in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Morgan Stanley held 1,457,333 shares of Nuvation Bio worth $8.28M as of Q2 2026.
  • Morgan Stanley sold 413,884 Nuvation Bio shares in Q2 2026, an estimated $2.02M.
  • Nuvation Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3854 holding.
  • Morgan Stanley first reported a position in Nuvation Bio in Q4 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Nuvation Bio position peaked at $11.4M in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.